The Health and Economic Impact of the Adult-specific 21-valent (aPCV21) Pneumococcal Conjugate Vaccine vs PCV20 on Invasive Pneumococcal Disease Among Adults Aged 65 years in the United Kingdom: A Modeling Study
Preprint
Abstract
Introduction: This study compared the health and economic impact of the 21-valent pneumococcal conjugate vaccine (aPCV21) vs the 20-valent pneumococcal conjugate vaccine (PCV20) on invasive pneumococcal disease (IPD) and post-meningitis sequelae (PMS) among adults aged 65 years and older in the United Kingdom (UK). Methods: A published Markov model was used to simulate a single-cohort of vaccine-naïve adults who became eligible for age-based vaccination at age 65 years, with uptake occurring over time. The cohort was followed until a maximum age of 100 years. Model inputs were derived from publicly available national health data and published reports. Outcomes were discounted at 3.5% annually, and costs were adjusted to the 2024 Great Britain Pound (£). Additional analyses explored the impact of changing the age-based recommendation from 65 years to 75 years. Scenarios involving instantaneous vaccine uptake rates were included as part of the sensitivity analyses. A deterministic sensitivity analysis was performed on the incremental direct medical costs between vaccinating with aPCV21 vs PCV20 under the age-based recommendation of 65 years. Results: Using an age-based recommendation of 65 years, aPCV21 led to fewer cases, deaths, and costs than PCV20. Compared with PCV20, aPCV21 averted an additional 138 IPD cases, 1 PMS case, and 22 IPD deaths, saving £1.2 million in direct medical costs. Raising the age-based recommendation from 65 to 75 years and using aPCV21 (or PCV20, respectively), resulted in 120 (92) additional IPD cases, 2 (1) additional PMS case(s), 19 (14) additional IPD death(s), and an extra £1.1 (£0.8) million in direct medical costs. The deterministic sensitivity analysis showed that aPCV21 reduced direct medical costs across all parameter ranges. Conclusions: Compared with PCV20, aPCV21 prevented more IPD cases, IPD deaths, and direct medical costs among older adults in the UK. Changing the age-based recommendation from age 65 to 75 resulted in worse health and economic outcomes.Keywords
This publication has 29 references indexed in Scilit:
- Pneumococcal vaccination for new residents entering older adult care homes in England: national observational surveillance studyThe Lancet Healthy Longevity, 2025
- Modelling the Epidemiological Impact of Different Adult Pneumococcal Vaccination Strategies in the United KingdomInfectious Diseases and Therapy, 2025
- Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United StatesInfectious Diseases and Therapy, 2024
- Lifetime Health and Economic Burden of Invasive Pneumococcal Diseases Attributable to V116 Serotypes Among Adults in the United StatesInfectious Diseases and Therapy, 2024
- The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in EnglandVaccine, 2024
- Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policiesVaccine, 2023
- Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adultsVaccine, 2023
- Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and WaleseClinicalMedicine, 2018
- The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in AustraliaVaccine, 2018
- The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in EnglandJournal of Infection, 2012